[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366720-105":3,"doc-detail-366720-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","limch1-inhibits-antitumor-immunity-by-upregulating-pdl1-in-triple-negative-breast-cancer","LIMCH1 inhibits antitumor immunity by upregulating PDL1 in triple-negative breast cancer","","Background: Breast cancer remains common worldwide, while triple-negative breast cancer (TNBC) shows limited treatment efficacy despite advances in immunotherapy. LIMCH1 is a relatively understudied LIM-domain protein implicated in cytoskeletal regulation and multiple cancers. This study investigates LIMCH1 expression and its functional impact in breast cancer. Methods: LIMCH1 prognostic value was analyzed using TCGA and expression validated by IHC tissue microarrays. LIMCH1 overexpression/knockdown TNBC models were tested via proliferation and migration assays, and immune changes were assessed by flow cytometry, immunofluorescence, Western blotting, and a mouse xenograft model. Results show LIMCH1 promotes tumor activity by upregulating PD-L1 via MAPK activation and enhancing immune evasion.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/limch1-inhibits-antitumor-immunity-by-upregulating-pdl1-in-triple-negative-breast-cancer/366720/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/limch1-inhibits-antitumor-immunity-by-upregulating-pdl1-in-triple-negative-breast-cancer/366720.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this study on TNBC?","Question",{"text":63,"@type":64},"The study examines how LIMCH1 expression affects antitumor immunity and tumor behavior in triple-negative breast cancer, emphasizing its regulation of PD-L1 and the resulting immunosuppressive microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the authors evaluate LIMCH1’s role experimentally?",{"text":68,"@type":64},"They analyze prognostic links using TCGA, validate expression by immunohistochemistry on breast cancer tissue microarrays, and test LIMCH1 overexpression or knockdown in TNBC cells using proliferation and migration assays. Immune changes are measured with flow cytometry, immunofluorescence, Western blotting, and a mouse xenograft model.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism does the study propose for LIMCH1-mediated immune suppression?",{"text":72,"@type":64},"The study indicates that LIMCH1 upregulates PD-L1 through MAPK pathway activation and suppresses CD4+ and CD8+ T-cell infiltration, promoting an immunosuppressive tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366720,1790964330,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8",8,"Qiu etal. Cell Communication and Signaling (2025) 23:419  \n[https://doi.org/10.1186/s12964-025-02387-6](https://doi.org/10.1186/s12964-025-02387-6)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nLIMCH1 inhibits antitumor immunity  by upregulating PDL1 in triple-negative breast cancer  \nMinghan Qiu 1,2,4,5†, Zhanhua Gao 1,5†, MengranTian 1,5†, Yuya Liu5†, Jinpu Liu5, Qiaonan Zhang5, Ruxue Liu6, Yayun Wang5, Xiangqian Zheng7, Jie Hao 1,3*, Zhen Yang3* and Ming Gao 1,3*  \nAbstract  \nBackground Breast cancer is one of the most common malignancies globally. Despite advancements in treatment, efficacy for certain subtypes such as triple-negative breast cancer (TNBC) remains limited. Immunotherapy has provided new hope for advanced breast cancer, particularly triple-negative breast cancer (TNBC), though its effectiveness varies by tumor type and patient differences. LIMCH1, a relatively understudied LIM-domain protein, has been linked to cytoskeletal regulation and various cancers, including lung, cervical, and renal carcinoma. This study aims to investigate LIMCH1 expression and its impact in breast cancer.  \nMethods The prognostic role of LIMCH1 in multiple cancers was analyzed using theTCGA database, and its expression in breast cancer was validated through immunohistochemistry (IHC) on breast cancer tissue microarrays. LIMCH1 overexpression and knockdown TNBC cell lines were constructed, and CCK-8, colony formation, transwell migration, and wound healing assays were performed to assess the effect of LIMCH1 on cell proliferation and migration. PD-L1 expression and selected immune-related proteins, such as CD3, CD4, CD8, and p-ERK1/2, were evaluated by flow cytometry, immunofluorescence, or Western blotting. A mouse al lograft model was established to evaluate LIMCH1’s role in tumor growth and T-cell infiltration within the TIME.  \nResults LIMCH1 was highly expressed in breast cancer and associated with poor prognosis. Bioinformatics analysis revealed that high LIMCH1 expression correlates with an immunosuppressive state. Functional assays showed  \nthat LIMCH1 overexpression promoted proliferation and migration, while knockdown inhibited these phenotypes. Mechanistic studies indicated that LIMCH1 upregulated PD-L1 via MAPK pathway activation, suppressed CD4 +and CD8 + T-cell infiltration, and led to an immunosuppressive tumor microenvironment. High LIMCH1 expression was also linked to low response rates to anti-PD-1 therapy, suggesting it may influence immunotherapy efficacy.  \n†Minghan Qiu, Zhanhua Gao, MengranTian and Yuya Liu contributed equally to this work.  \n*Correspondence: Jie Hao [haojie1215@126.com](haojie1215@126.com)[ ](haojie1215@126.com)Zhen Yang [yangz_tumc@126.com](yangz_tumc@126.com)[ ](yangz_tumc@126.com)Ming Gao  \n[headandneck2008@126.com](headandneck2008@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \n","cbCaihkiXiynXrAN","https://ap.wps.com/l/cbCaihkiXiynXrAN","pdf",9162323,18,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the main focus of this study on TNBC?\",\"answer\":\"The study examines how LIMCH1 expression affects antitumor immunity and tumor behavior in triple-negative breast cancer, emphasizing its regulation of PD-L1 and the resulting immunosuppressive microenvironment.\"},{\"question\":\"How do the authors evaluate LIMCH1’s role experimentally?\",\"answer\":\"They analyze prognostic links using TCGA, validate expression by immunohistochemistry on breast cancer tissue microarrays, and test LIMCH1 overexpression or knockdown in TNBC cells using proliferation and migration assays. Immune changes are measured with flow cytometry, immunofluorescence, Western blotting, and a mouse xenograft model.\"},{\"question\":\"What mechanism does the study propose for LIMCH1-mediated immune suppression?\",\"answer\":\"The study indicates that LIMCH1 upregulates PD-L1 through MAPK pathway activation and suppresses CD4+ and CD8+ T-cell infiltration, promoting an immunosuppressive tumor microenvironment.\"}]","LIMCH1 inhibits antitumor immunity by upregulating PDL1 in triple-negative breast cancer | PDF",1790166853,45,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14d1dee24bd971b2496ac833f254a36a.webp",983,1310,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbdc88a173d09a4bc3633b452512b99b.webp",982,1309,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7306c301400b10745512c2bd08df9552.webp",981,1308,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64a93592ca857292fb9703e87ebe5a4b.webp",980,1306,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]